Short-term Results of Carotid Stenting for the Treatment of Extracranial Carotid Occlusive Disease.
Fu Wei-guo,Zhu Ting,Chen Bin,Jiang Jun-hao,Yang Jue,Shi Zen-yu
DOI: https://doi.org/10.1097/00029330-200606010-00015
2006-01-01
Abstract:Carotid artery angioplasty and stenting (CAS) has been performed with increasing frequency for the treatment of extracranial carotid occlusive diseases (ECOD) in recent years. Its feasibility and safety are supported by the Stenting and Angioplasty with Protection in Patient at High Risk for Endarterectomy (SAPPHIRE) trial,1 which revealed a lower incidence of death, stroke and myocardial infarction compared with carotid endarterectomy (CEA) in high-risk patients. However, it is a pity that up to now, initial results of this endovascular procedure have yet been infrequently documented in China. This retrospective study was to analyze the short-term results of CAS to treat ECOD in a single medical center. METHODS Patients We retrospectively reviewed data collected from a registry of 51 consecutive patients who underwent elective CAS at our hospital between January 2003 and September 2005. Complete data were available for 48 of these patients. All patients underwent preoperative duplex ultrasound scanning and magnetic resource angiography along with a complete evaluation by a radiologist. These tests were used to determine the degree of stenosis and assess the lesion for calcification, thrombus and ulceration. All findings were subsequently confirmed by digital subtraction angiography before the CAS. The therapeutic indications for intervention were based on the following:2 (1) symptomatic stenosis >50% and asymptomatic stenosis >70% (the degree of stenosis was determined by angiography by using European Carotid Surgery Trial measurement criteria); (2) combining one or more high risk factors for surgery. We used the following definitions of patients at high-risk for surgery: (1) severe dysfunctions such as New York Heart Association (NYHA) class III and IV or left ventricular ejection fraction (LVEF)<30%; (2) myocardial infarctions with impaired LVEF or unstable angina are investigated by stress test, coronarography or both. Severe coronarography stenosis requiring treatment is discussed for PTCA or CABG staged or combined procedures can be planned according to the symptoms and their priority; (3) severe pulmonary dysfunction [forced expiratory volume in 1 second (FEV1) <1 L]; (4) patients with contralateral carotid stenosis > 50% or more or completely occlusion or a non-patent Wllis's circle and intracranial tandem lesions are considered for CAS with protection devices not interrupting the flow rather than CEA with shunting; (3) age >60 years. Patients were excluded from CAS if they had aortic arch anatomy that precluded access, severely tortuous or elongated internal carotid artery (ICA), or total occlusion of target vessels. This study was not carried out under a research protocol, but the risks and benefits of CAS compared with CEA were reviewed in detail with each patient before proceeding with CAS and this review was approved by the group of vascular surgeons, radiologists and neurologists. Procedure All patients received either clopidogrel 75 mg/d or aspirin 100 mg/d for 1 week, in addition they were given Nimotop 2.4 ml/h throughout the perioperative period in order to control the blood pressure lower than 140/90 mmHg. Mannitol was used 125 ml/12h for 2—3 days, so that the intracranial high-perfusion injury may be avoided. Procedures were performed in a radiology suite with a fixed GE system (GE medical Systems) with a 16-inch image intensifier. An anesthesiologist was present throughout the whole procedure. Whole intervention procedures were performed under local or general anesthesia and an arterial catheter was placed for monitoring blood pressure. A 5F sheath was placed in the common femoral artery by the seldinger technique. An angiogram was performed of the aortic arch and great vessels via a 4F pigtail catheter. Heparin was given intravenously to achieve an activated clotting time (ACT) more than 200 seconds with 5000–6000 units. The affected carotid artery was selectively catheterized with angled glide catheter (Johnson & Johnson, USA). A selective carotid cervical and cerebral angiogram was performed at least in 2 views. A road map artériographic image of the bifurcation was then obtained. After confirmation of the lesion, the catheter was advanced over a 0.035-inch glide wire into the external carotid artery (ECA) with use of the road map image, and a long Amplatz (Boston Scientific, USA) wire (260 cm) was used to exchange the 5F sheath to a 90-cm 7F introducer (Cook). The introducer with its inner dilator was advanced into the common carotid artery (CCA) proximal to the carotid bifurcation. The lesion was crossed with the distal cerebral protection devices (DCPD) and the filter was deployed in a straight portion of ICA at least 2cm distal far from the lesion. A self-expanding stent was delivered and deployed across the lesion. If necessary, pre- or postdilation was performed with a 4—6 mm balloon. Care was taken not to overdilate to a diameter larger than the distal ICA. When a filter was used, a completion angiogram was performed and the filter was recaptured. Heart rate and blood pressure were monitored continuously after the procedures for at least 24 hours, and one week later, patients were discharged to home with aspirin (100 mg/d) and clopidogrel (75 mg/d) orally for at least half a year. Carotid duplex scanning was followed up at 6 months and yearly there after. Follow-up Patients underwent a neurologic examination performed by the surgical visiting doctors on postoperative day 1 and at each clinic visit. Any new neurologic deficits were scored with the National Institutes of Health (NIH) Stroke Scale.3 A major stroke was defined as a new neurologic event that lasted longer than 24 hours, with an increase in the NIH Stroke Scale greater than 3. A minor stroke was defined as a new neurologic event that lasted longer than 24 hours and was associated with an increase in the NIH Stroke Seale of less than 3. A transient ischemic attack (TIA) was defined as a new neurologic deficit that lasted less than 24 hours. Myocardial infarction was defined as a troponin T level greater than 0.03 ng/ml or an abnormal postoperative electrocardiogram compared with preoperative findings suggestive of myocardial infarction. Carotid sinus compression syndrome (CSCS) was defined as bradycardial (HR<40 bpm or decrease ≤ 50%) or hypotension (systolic blood pressure < 90 mmHg or mean arterial pressure <50 mmHg). In-stent recurrent stenosis (ISRS) was defined as stenosis > 50% with duplex ultrasound scanning criteria. Statistical analysis All values obtained are expressed as the mean± standard error (SE). All data were statistically analyzed with chi-square or t test by SPSS 11.5. Multivariate statistical analysis was performed using the Logistic regression, which remains statistically unquestionable even with small numbers of individuals. P value less than 0.05 was considered statistically significant. RESULTS Demographic data Forty-eight CAS were performed in 48 patients with DCPD in 95.8% (46/48), 91.7% (44/48) men and 8.3% (4/48) women, mean age (70.6±5.9) years. Preoperative asymptomatic cases were 37.5% (18/48), sympotomatic cases were 62.5% (30/48). Preoperative symptoms were mainly TIA in 27.1% (13/48) of 48 patients. Only 16.7% (8/48) of the symptomatic patients had minor stroke, and 25.0% (12/48) had major strokes. Mean internal carotid artery diameter stenosis was (71.2 ±14.8)%. We had 25.0% (12/48) patients with cardiac risks, 66.7% (32/48) with hypertension, 10.4% (4/48) with pulmonary dysfunction, 25.0% (12/48) with other vascular diseases, 29.2% (14/48) had hyperlipidemia, and 20.8% (10/48) had diabetes mellitus. Patients with single preoperative risk factor were 43.8% (21/48); two or more of these factors were 47.9% (23/48). In 33.3% (16/48) cases the contralateral carotid artery had 50% or greater stenosis or was completely occluded. Perioperative data All patients (100%) suffered a femoral approach. Only self-expanding stents were used in our series. The types of stent deployed were Precise Rx (Cordis, USA) 70.8% (34/48), Wall-stent (Boston Scientific, USA) 22.9% (11/48), Comformexx (Bard, USA) 4.2% (2/48) and Wall-graft (Boston Scientific, USA) 2.1% (1/48), mean stent diameter (8.0 ± 0.9) mm and length was (37.6 ± 7.2) mm. Two different DCPD were used in our study: FilterWire (Boston Scientific, USA) 25.0% (12/48); Angioguard Rx (Cordis, USA) 70.8% (34/48) and 4.2% (2/48) patients did not use the filter. All filters had a pore size <200 mm and visible debris was present in the filter 30.4% (14/46). Pre- or postdilation was performed in 37.5% (18/48) and 4-mm balloon was used in 8.3% (4/48) patients, 5-mm was 16.7% (8/48) and 6-mm was 10.4% (5/48). Mean operative time was (80.2 ± 6.3) minutes, fluoroscopy time was (27.7 ± 3.6) minutes, and mean volume of contrast agent (Vispaque, USA) was (88.2 ± 5.7) ml. Early outcome (within 30 days) The technical success rate was 100% (48/48), without deaths, major or minor strokes within 30 days. TIA occurred in 4.2% (2/48) of patients. Postoperative CSCS requiring pharmacologic treatment occurred in 18.8% (9/48) of patients. No myocardial infarction occurred postoperatively. The Logistic test on risk factors and comorbidities showed that the higher incidence of postoperative neurologic complications and CSCS were both independently associated with the periprocedure pre- or postdilation (P=0.008, P=0.020), and the risks of these two postoperative adverse events was significantly elevated when the diameter of dilation balloon was more than 5 mm (P=0.005 P=0.028). It was worth mention that the volume of contrast agent (P=0.056) and fluoroscopy time (P=0.073) had a probability of having postoperative neurologic complications. The diameter and length of stents and the type of DCPD showed no incidence on neurologic complication (P=0.726, P=0.116, P=0.676). Follow-up (> 30 days) No stent deformity happened and 4.2% (2/48) ISRS were found by color duplex scanning. The restenosis rates at 6 months, 1 year and 2 years was 2.1% (1/48), 2.1% (1/48) and 0 respectively. Among all related variances, no risk factor or comorbidity was found to be an independent predictor of ISRS with Logistic test, but having other vascular diseases preoperatively was a potential predictor for the ISRS (P=0.053). DISCUSSION CAS is rapidly becoming accepted as an alternative to CEA for the treatment of extracranial carotid occlusive disease. Although the indications remain controversial, its safety and feasibility are no longer questionable. The SAPPHIRE Trial firstly demonstrated the better outcome in CAS group compared with CEA group. They observed a 30-day multiple adverse events rate of 5.8% in CAS, compared with 12.6% in CEA.1 However, whether the results can be explorated to a patient population at low risk is still unknown. At present, Hobson4 is performing an NIH-sponsored trial that seeks to address this question. Our issue demonstrated a death and stroke rate lower than that reported by SAPPHIRE trial. There may be several explanations as following: first, this is because our single center experience is tending to have lower complication rate than those reported in abroad multi-center trials. We are ready to perform a large sample trial, which cooperated with other domestic vascular centers. Secondly, the patients were not examined by an independent protocol neurologist. As in the SAPPHIRE trial, we may have detected more subtle neurologic deficits or something different again. The long-term outcome of CAS has been poorly documented. Some authors reported short-term results of protected CAS, with a neurologic stroke rate <3%.2 Offering an average follow-up of 12 months over a 33-month period, our series show the new neurologic events is 4.2% (2/48), and they both happened in 30 days. We also found in this study that pre- or postdilation was independently associated with an increased rate of neurologic complications and these adverse events were significantly elevated when the diameter of dilation balloon was > 5 mm. In this research, patients suffered pre- or postdilation fewer than reported in west. We preferred this because the possibility of cerebral microembolization was concerned. Previously, we had demonstrated that the unstable plaque (mainly the low echo plaque) was easy to be cut and exfoliate following periprocedure dilation, which attend to the distal embolization directly.5 On the other hand, the continuous distention of the self-expanding stent itself is the other area we should consider. So in our opinion, there is unnecessary for everyone to have the pre- or postdilation. Moreover, it was worth mention that Patrice et al2 identified age >70 years, man, renal insufficiency, and lesion located at bifurcation were also good predictors of early and late neurologic complications as well as other issues6–8 demonstrated old age, preoperative symptoms, length of the lesion, and echogenicity of the plague as predictors for early new neurologic events. Except that, some other trials did not encourage such observation. They addressed that the postoperative stroke be associated with the presence of visible debris, but not by other patient-related variables. Sprouse et al9 identified four individual factors predictive for visible debris were hypertension, hypercholesterolemia, stent ≥ 9 mm and procedure-related neurologic event. In our series, there were 27.1% (13/48) patients suffered stent ≥9 mm, and the difference was not significant compared with patients deployed with other size stent. And the length of the stent was not predictive either. The use of DCPD in CAS is still controversial. The key problem is the indications have not been regulated. Two different DCPD were used in all but two patients in this study because of no supplying in early experience. Although previous trials have demonstrated that the use of DCPD is safe enough, to date no random report has supported the significant superiority during perioperative procedure. Kastrup et al10 encouraged the use of DCPD. They have shown a reduction in neurologic events, from 5.5% to 1.8%. Similarly, Wholey et al11 reported a stroke and death rate of 4.2% without DCPD and 1.7% with protection. However, Mlekusch et al12 found visible debris in filters occupied 60%, suggesting the filter did not prevent macroem-bolization in the remaining 40% and was likely not necessary for a good outcome. Elimination of DCPD not only could reduce the hospitalization expense, but also did avoid the DCPD-related complications. But in spite of it, the use of DCPD still has become more and more acceptable as CAS developed. Carotid sinus compressing syndrome (CSCS) have been observed after CAS with the reported incident of 7%—76%.12–14 The causative factor is considered to be stimulation of the carotid sinus baroreceptors by the angioplasty balloon and endovascular stent. Stimulation of baroreceptors located in the carotid bifurcation causes an increase in afferent signals via the carotid sinus and glossopharyngeal nerves to the caudal medulla. The medulla then regulates a temporary increase in parasympathetic impulses and a decrease in sympathetic vascular tone, with result of bradycardia and hypotension. Overall incidence of bradycardia and/or hypotension was 18.8% (9/48); we did find that pre- or postdilation was the significant predictor for CSCS. Other studies found demographic factors associated with CSCS after CAS, such as the increased age, coronary heart disease, myocardial infarction and the history of symptomatic carotid disease.12,13 Dargas et al14 observed 44% cases with postoperative CSCS were preceded by intraprocedural hypotension, and Qureshi et al13 found intraprocedural hypotension was the strongest predictor of postoprocedual CSCS. Most of all prior studies suggest that prophylactic atropine may decrease the incidence of CSCS and cardiac morbidity in patients with primary lesions undergoing CAS and recommend consideration of routine prophylactic atropine administration in such patients with 0.5—1.0 mg dosage.15 However, it should also be recognized the well-known side effect of atropine, tachycardia. With resultant tachycardia, there is an increased cardiac oxygen demand that may result in an increased incidence of myocardial infarction. Considering the above reasons, we did not give prophylactic atropine to our patients in this study. The unknown incidence of in-stent recurrent stenosis (ISRS) is an additional area of concern with CAS. Richard16 and Criado17 both reported a rate of 3%, Henry18 of 4.7% and Bergeron2 of 6.8%. These ISRS rate were similar and had significant difference with restenosis after endarterectomy, ranged from 4% to 22%.2 In our observation, the ISRS rate for lesions narrowing the lumen >50% was 2.1% (1/48) at 6-month follow-up. As a result of limited follow-up in our group of patient, the durability of this procedure needs further evaluation. Which factors will predict ISRS? The asymptomatic lesions, using of balloon expandable stent, and postendarterectomy stenosis have been identified.2 In this study, we do not find any significant predictor for ISRS. This may be due to our relatively small number of sample, but it is interesting to rate the only factor approached statistical significance in our cohort has other vascular diseases. In our past experience, the insufficient use of anti-platelet aggregation drugs (< 3 months) and pre- or postdilation in procedure may lead to a higher ISRS rate, but such findings still need the longer follow-up. Which pathologic lesion does play the more important role to ISRS, the hyperplesia of vascular intima resulted from the implanted stent or the thrombosis secondary to the injuring of the endothelial layer? This question will be investigated in future works. In conclusion, our single-center experience with CAS, mainly in patients at high risk, is comparable with our own concurrent CEA experience, although the follow-up is too short to assess the ultimate durability of CAS. So a more long-term follow-up and a randomized trial cooperated with other domestic vascular centers are necessary to evaluate this technique.